SNTI - Senti Bio Enters Strategic Collaboration with Celest Therapeutics to Develop SENTI-301A in China

2023-11-07 09:36:16 ET

DENVER, Colo., Nov 7, 2023 ( www.247marketnews.com )- Senti Biosciences Inc. (NASDAQ: SNTI) stated, after yesterday’s market close, that it entered a new strategic collaboration with Celest Therapeutics, a China-based biotechnology company, for the clinical development of SENTI-301A to treat solid tumors in China.

Celest will lead clinical development, with technical support from Senti Bio, with the first patient expected to be enrolled in China in the first half of 2024, while Senti Bio is eligible to receive up to $156 million in milestones and royalties from the deal.

Senti Biosciences is trading at $0.5903, up $0.2983 (+102.16%) on 16.3M premarket shares.

Its 52-week range is $0.2701 to $2.75. It set a new 52-week low late October, but bounced well …

The post Senti Bio Enters Strategic Collaboration with Celest Therapeutics to Develop SENTI-301A in China appeared first on 24/7 Market News .

For further details see: